Clinical Trial Update: Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating adding ofatumumab to reduced intensity conditioning for high-risk chronic lymphocytic leukemia patients undergoing allogeneic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: Grupo Espanol de trasplantes hematopoyeticos y terapia celular | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED